A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Subjects from 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis

Date Added
January 31st, 2024
PRO Number
Pro00130368
Researcher
Lara Wine Lee

List of Studies


Keywords
Children's Health, Skin
Summary

This study is being done to learn more about apremilast (AMG 407) in mild to moderate plaque psoriasis in participants (children and adolescents) aged 6 to 17 years. It will see whether it causes any side effects. About 50 people are expected to take part in this study. The duration of the study is approximately 285 days. This includes 3 phases: 35 days of screening phase, 225 days (32 weeks) of treatment phase, and 60 days of observational follow-up phase after the last dose of study drug – this means drug is still being tested to see if it is safe and works.

Institution
MUSC
Recruitment Contact
Courtney Rowley
843-792-9784
rowle@musc.edu

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment

Date Added
January 8th, 2024
PRO Number
Pro00132759
Researcher
Lara Wine Lee

List of Studies


Keywords
Adolescents, Skin
Summary

The purpose of this study is to evaluate the efficacy of JNJ-77242113 in participants with moderate to severe plaque psoriasis. The total duration of this study for each participant is approximately 165 weeks, which includes a 5-week screening period, a placebo-controlled period through Week 16 and a randomized withdrawal and retreatment period from Week 24 through Week 52. At Week 52, participants will be transitioned to open-label JNJ-77242113 through Week 156 and a 4-week safety follow-up period will be observed for participants who discontinue study intervention during the study or at the end of the treatment period.

Institution
MUSC
Recruitment Contact
Madeline Richmond
843-792-1436
richmoma@musc.edu

A 2-part, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate-to-Severe Pruritus in Adult Subjects With Notalgia Paresthetica

Date Added
January 2nd, 2024
PRO Number
Pro00130543
Researcher
Lara Wine Lee

List of Studies


Keywords
Skin
Summary

This is Phase 2, 2-part, placebo-controlled study to evaluate the efficacy of the oral medication Difelikefalin at 3 different dose levels (0.25 mg, 1 mg, 2 mg BID) for Moderate-to-Severe Pruritus in Adult Subjects With Notalgia Paresthetica. Study participants will participate in Part A or Part B of the study. If you are eligible to take part in this study, you will be randomly assigned to one of 4 study treatment arms during Part A of the study.
• Arm 1: Difelikefalin 0.25 mg
• Arm 2: Difelikefalin 1 mg
• Arm 3: Difelikefalin 2 mg
• Arm 4: placebo
Participants enrolling in Part B will be randomized in a 1:1 ratio receiving either Difelikefalin or placebo. The dose of Difelikefalin will be determined by the results of Part A. The duration of Blinded Treatment: Part A: 8 weeks, Part B: 8 weeks. A 52 week Open-label extension (OLE) is available for participants enrolling in Part B. During the OLE, participants. Difelikefalin will be administered in the same dose as Part B.

Institution
MUSC
Recruitment Contact
Tiffany Vereen
843-792-6882
vereent@musc.edu

A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET – VOYAGER)

Date Added
October 10th, 2023
PRO Number
Pro00130467
Researcher
Lara Wine Lee

List of Studies


Keywords
Drug Studies, Skin
Summary

The study is being conducted in order to learn about the development of immunization responses against two vaccines (tetanus vaccine and meningococcal vaccine) in adults with moderate-to-severe atopic dermatitis (AD) who are treated with the study drug, rocatinlimab, versus a placebo. Subjects with moderate-to-severe AD will be randomized 2:1 to either rocatinlimab or placebo every 4 weeks for 24 weeks. The maximum study duration will be approximately 40 weeks, including a screening period of up to approximately 4 weeks, a 24-week treatment period, and a 16-week safety follow-up period after the last dose of investigational product at week 20.

Institution
MUSC
Recruitment Contact
Mikayla DiDonato
843-876-2281
didonato@musc.edu

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Baricitinib in Children from 6 Years to Less than 18 Years of Age with Alopecia Areata

Date Added
September 11th, 2023
PRO Number
Pro00126611
Researcher
Lara Wine Lee

List of Studies


Keywords
Pediatrics, Skin
Summary

This is a Phase 3, placebo-controlled, randomized, double-blind research study evaluating the efficacy, safety, and PK of baricitinib in children from 6 years to less than 18 years of age with severe alopecia areata. The study is divided into 4 periods: a 5-week screening period, a 36-week double-blind treatment period, an approximately 2-year long-term extension period, and a 4-week posttreatment follow-up period. If the subject meets all eligibility criteria they will be randomized to receive either baricitinib high dose, baricitinib low dose, or placebo for 36 weeks. Participants will then be transitioned into the long-term extension treatment period. Subjects will attend 18 clinic visits for up to 145 weeks.

Institution
MUSC
Recruitment Contact
Madeline Richmond
8437921436
richmoma@musc.edu

A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome

Date Added
August 28th, 2023
PRO Number
Pro00128405
Researcher
Lara Wine Lee

List of Studies


Keywords
Skin
Summary

This is a multi-center, randomized, double-blind, placebo-controlled, phase II/III study to evaluate the efficacy and safety of spesolimab compared to placebo in the treatment of Netherton syndrome. This study will last up to 72 weeks with 16 clinic visits. Eligible patients will be randomized 2:1 to receive either spesolimab i.v. loading doses at Week 0 plus spesolimab subcutaneous doses every 4 weeks, or to receive placebo i.v. loading dose at Week 0 plus placebo subcutaneous doses every 4 weeks. At Week 20, all patients will enter the open label period to receive spesolimab subcutaneous dose every 4 weeks up to Week 52. There will be a safety follow up visit 16 weeks after the last dose.

Institution
MUSC
Recruitment Contact
Mikayla DiDonato
843-876-2281
didonato@musc.edu

Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1.

Date Added
August 17th, 2023
PRO Number
Pro00129550
Researcher
Lara Wine Lee

List of Studies


Keywords
Skin
Summary

This is an international, Phase IIb/III multi-center, double-blind, placebo-controlled, randomised trial assessing the efficacy and safety of spesolimab versus placebo in patients with moderate to severe HS. Approximately 200 trial participants in Part 1 (Phase IIb) and 260 trial participants in Part 2 (Phase III) will be randomised. For Part 1, after signing the informed consent, trial participants will enter the screening period for up to 28 days, and if all eligibility criteria are met, trial participants will be randomised in a 1:1:1:1 ratio to either active group, including high dose, medium dose, and low dose group, or placebo group. Once randomised, trial participants will start a treatment period of 50 weeks. Administration of treatment will be up to Week 48.

Institution
MUSC
Recruitment Contact
Tiffany Vereen
843-792-6882
vereent@musc.edu

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis

Date Added
August 2nd, 2023
PRO Number
Pro00128776
Researcher
Lara Wine Lee

List of Studies


Keywords
Skin
Summary

The purpose of this research study is to determine if an investigational cream, ruxolitinib 1.5% cream, is safe and effective to treat adults with prurigo nodularis. In this study, ruxolitinib cream will be compared to a "vehicle cream." The vehicle cream looks like the ruxolitinib cream but contains no ruxolitinib. This study can last up to 60 weeks, including up to 4 weeks for screening, up to 52 weeks for treatment, and 30 days for safety follow-up. Eligible participants will be randomized 1:1 to receive ruxolitinib 1.5% cream or vehicle cream for the first 12 weeks. For the following 40 weeks all participants will receive the ruxolitinib cream.

Institution
MUSC
Recruitment Contact
Tiffany Vereen
843-792-6882
vereent@musc.edu

A Phase 3, Multicenter, Long-Term Extension Study to Assess the Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age with Moderate-to-Severe Atopic Dermatitis

Date Added
June 19th, 2023
PRO Number
Pro00128287
Researcher
Lara Wine Lee

List of Studies


Keywords
Children's Health, Skin
Summary

This Phase 3 study is designed to assess the long-term safety and efficacy of lebrikizumab in participants 6 months to <18 years of age with moderate-to-severe AD. Participants who have completed Study KGBI through Week 16 without requiring the use of systemic rescue medication will be eligible to enroll into Study KGBJ. All participants will receive active lebrikizumab treatment during Study KGBJ. The planned duration of treatment for each participant is approximately 52 weeks. All participants will enter a post-treatment safety follow-up period approximately 12 weeks after the last dose of lebrikizumab. This study will include both on-site (in clinic) and remote visits (telephone calls).

Institution
MUSC
Recruitment Contact
Mikayla DiDonato
843-876-2281
didonato@musc.edu

Cold Atmospheric Plasma Device for the Treatment of Molluscum Contagiosum and Verruca Vulgaris in Pediatric Patients - Open-Label Extension Study

Date Added
June 6th, 2023
PRO Number
Pro00127338
Researcher
Lara Wine Lee

List of Studies


Keywords
Children's Health, Pediatrics, Skin
Summary

Patients between 4-21 years of age with at least one wart or molluscum lesion are eligible to participate in this study. The duration of the study is a minimum of 4 weeks with the maximum duration of monthly treatments for one year, depending on lesion clearance. The number of lesions will be chosen by the dermatologist. Patients who opt to participate will receive non-thermal, or cold, atmospheric plasma to treat all lesions selected. Safety profile as well as changes in size, pain and appearance will be measured. Photographs and dermatologist impressions will be used to measure treatment response.

Institution
MUSC
Recruitment Contact
Courtney Rowley
843-792-9784
rowle@ musc



-- OR --